
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health is a promising company with a positive outlook due to recent regulatory approvals and potential breakthrough treatments for obesity and type 2 diabetes. Their lead product candidate, Revita, has shown promising results in weight loss and is set to enter Phase 1/2 trials. The company's streamlined regulatory pathway and potential De Novo reclassification could further accelerate Revita's development and commercialization, adding value to the company and its stock. Additionally, Revita's ability to maintain weight loss and potential to replace chronic drug therapy make it a promising option for the treatment of metabolic diseases.
Bears say
Fractyl Health is currently facing challenges due to its Revita and Rejuva candidates being in the clinical stage and the lack of significant changes in levels of HbA1c in its patients. Moreover, the company's REMAIN-1 pivotal readout in 4Q26 is a binary event with high stakes, as it will determine the potential approval of Revita as a first-in-class procedural therapy for weight maintenance. While the company's projected visual representations of the two endpoints and positive view on the trial success may suggest a potential turnaround in the future, the current risks and uncertainties make us skeptical about the company's financial outlook.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares